What holds up
Aim for at least 250 minutes of physical activity per week (approximately 35 minutes per day), ideally split into 150 minutes of moderate cardio and 100 minutes of muscle strengthening, while keeping in mind that women benefit from improvements in longevity and blood pressure at effort volumes often lower than those of men.
Mary Claire Haver's advice is supported by robust public health data. The 150 minutes of moderate cardio per week are perfectly aligned with global benchmarks validated by large population follow-up studies (Piercy 2018, Bull/WHO 2020) to preserve cardiovascular well-being. For strength training, a meta-analysis by Shailendra (2022) shows that approximately 60 minutes per week is already sufficient to optimize life expectancy, which proves that the positive impact begins very early. The female advantage—namely, obtaining equal or greater longevity gains at lower exercise volumes—is supported by a vast prospective cohort study (Ji 2024, JACC) and analyses of the NHANES database (He 2025). Finally, the specific link between strength training and reduced blood pressure in women is based on an observational study by Park & Park (2024). Although these population data are not all derived from randomized clinical trials (RCTs) that would prove a direct and isolated causality for every movement, this comprehensive exercise prescription remains scientifically sound for daily health.
The use of low-dose vaginal estrogen in postmenopausal women is associated with a 15% to 21% decrease in the risk of rectal cancer, in addition to the well-established benefits of this treatment for intimate comfort, tissue elasticity, and urinary protection.
The creator accurately cites the Finnish study by Siitonen et al. (published in the journal Maturitas), which is a large observational case-control study involving over one million women. This research highlights a correlation between low-dose vaginal estrogen and a reduction in the risk of rectal cancer ranging from 15% to 21%. The nuance provided by the creator is exemplary: he clarifies that this is an association and not a causal link, the latter of which would require validation through randomized controlled trials (RCTs). Furthermore, the other benefits described regarding intimate comfort, lubrication, and the prevention of recurrent urinary discomfort are strongly supported by numerous meta-analyses and clinical trials. This potential protective effect on the rectum, while clinically plausible through local diffusion, should therefore be viewed as a promising bonus rather than the primary reason for adopting this care regimen.
To protect their future vitality, menopausal women must ensure they adhere to the fundamental pillars of well-being: sufficient sleep, regular cardiovascular activity, and muscle strengthening to counter the effects of hormonal decline.
The observational study by Shillito et al. (2026), involving more than 10,000 women, confirms that a large proportion of menopausal women do not meet the recommendations regarding sleep and physical activity. Regarding the impact of hormonal change on the body, the review by Collins et al. (2019) shows how the decline in estrogen directly weakens muscle strength and bone structure. The estimates of a 15% loss in muscle mass and 10% loss in bone density are consistent with the narrative review by Buckinx and Aubertin-Leheudre (2022) on changes in physical condition after menopause. To counter this decline, the assertion that muscle strengthening supports longevity by 10% to 20% is solidly based on a large-scale meta-analysis conducted by Momma et al. (2022). Finally, the role of deep sleep in the clearance of cerebral metabolic waste and the regulation of blood glucose is well established by observational data on biological rhythms. This preventive and nuanced discourse is therefore perfectly aligned with the current state of wellness science.
Postmenopausal women have a 60 to 80% risk of having low vitamin D levels; it is therefore advised not to rely solely on diet to meet one's needs and to have one's blood levels tested by a professional.
The estimate of a 60 to 80% prevalence of low vitamin D levels in postmenopausal women is generally consistent with scientific literature. A meta-analysis published in the journal Maturitas confirms that vitamin D insufficiency is extremely common in postmenopausal women worldwide, frequently fluctuating within these percentages depending on region and season. Regarding diet, nutritional research validates the fact that food sources struggle to meet daily requirements, especially since the absorption of this vitamin depends on the presence of healthy fats during the meal. Regarding screening, expert opinion from the North American Menopause Society encourages the assessment of vitamin D levels in postmenopausal women in order to best adapt their lifestyle. Although systematic screening for individuals without any risk factors remains debated among certain health authorities, this personalized suggestion remains an excellent preventive practice to optimize one's well-being.
Get your vitamin D and triglyceride levels tested at the onset of menopause, as the drop in estrogen naturally increases cardiovascular risk. To address this, it is recommended to supplement with vitamin D, vitamin K2 (to guide calcium toward the bones rather than the arteries), and 2g of EPA-rich omega-3s to limit inflammation and regulate blood lipids.
The claim regarding the rise in triglycerides is based on a rigorous observational study published in Oxford Academic (2025) involving two highly active indigenous populations (the Tsimané and the Mosetén), confirming that for an identical lifestyle, the hormonal transition increases the risk of rising blood fats by a factor of 2.5. The direct impact of the drop in estrogen on lipid balance is, moreover, widely documented by long-term cohort studies. Regarding supplementation, a 2023 meta-analysis of randomized controlled trials (RCTs) confirms that omega-3s significantly decrease triglycerides in menopausal women. The recommended intake of 2g of EPA-rich omega-3s is entirely consistent with the guidelines of institutions like the American Heart Association for supporting cardiovascular health. As for the vitamin D and K2 duo, meta-analyses of RCTs validate the benefit of K2 for preserving bone strength and density post-menopause. However, the claim that K2 prevents calcium from depositing in the arteries relies primarily on a promising theoretical model (the 'calcium paradox') but still lacks direct and indisputable clinical evidence in humans. Finally, the suggestion to have your vitamin D and lipid levels measured through a simple check-up remains an excellent preventative practice.
Optimism is not merely an innate trait: it is estimated to be only 25% genetic (linked in particular to the oxytocin receptor gene), leaving the remaining 75% accessible through relational and cognitive skills that can be actively acquired.
This perspective is particularly solid and well-grounded in behavioral science. The estimate that optimism is approximately 25% hereditary comes from observational studies of twins (such as those summarized by Plomin et al.), which generally place genetic influence between 23% and 30%. Regarding the oxytocin receptor gene (OXTR), a major observational study published in the journal PNAS by Saphire-Bernstein and her team effectively correlated variations of this gene with optimism and resilience to stress. Finally, the idea that optimism is a skill that can be developed is scientifically demonstrated: a meta-analysis of randomized controlled trials (RCT) published by Malouff and Schutte in 2017 confirms that positive psychology interventions significantly increase participants' optimism. The creator avoids the pitfall of magical positive thinking by rightly insisting on mental training and the strength of social ties.
During menopause, the decline in estrogen affects the flexibility and sensitivity of the intimate area; however, these changes are not inevitable and can be greatly improved with appropriate local care.
The gradual decrease in hormone production during menopause alters the ecosystem and elasticity of the intimate area, which can lead to a loss of sensitivity and comfort. This phenomenon, known as genitourinary syndrome of menopause (GSM), is documented by consensus statements from professional health organizations such as the American Urological Association (expert opinion). Meta-analyses, notably from the Cochrane collaboration, and numerous randomized controlled trials (RCTs) demonstrate that the application of low-dose hormone-based local care (such as targeted moisturizing creams) helps restore natural hydration, regenerate delicate skin, and regain better sensitivity. The 'reversible' aspect mentioned by the creator is therefore observed in the elasticity and responsiveness of tissues through these targeted treatments. However, the overall loss of volume in the outer labia is also linked to the natural aging of skin tissues, which is not entirely corrected by these methods. Furthermore, other popular approaches such as intimate laser therapy still lack strong evidence, with some rigorous studies (RCTs) showing no superiority over a simple placebo effect.
If physical perimenopause symptoms (such as night sweats or hot flashes) regularly disrupt your sleep, it is advisable to seek ways to soothe them in order to maintain your current comfort and potentially support your long-term cognitive health.
The creator faithfully draws on an observational study from Harvard University (Hu et al., 'Menopause', 2026) showing that perimenopausal sleep disturbances, when linked to night sweats, are associated with slight declines in cognitive faculties decades later. This link is corroborated by other observational work, notably the SWAN study (2026) and research from the University of Pittsburgh (Thurston et al., 'Neurology', 2022), which link these nighttime awakenings to signals of brain vulnerability. The creator demonstrates remarkable rigor by pointing out the study's limitations himself, including its observational nature and the use of self-reported sleep data. The assertion that mere light sleep does not impact future mental agility is validated by this study, as no significant correlation was detected in women not awakened by these symptoms. Although no randomized controlled trial (RCT) yet proves that treating these awakenings prevents long-term decline in attention, recent randomized controlled trials ('Menopause', May 2026) demonstrate that targeted behavioral approaches greatly improve the quality of life and nighttime comfort of women. Taking care of one's nights during this life transition therefore remains an excellent overall strategy for optimizing vitality.
Our gut microbiota actively communicates with our hormones: a specific set of bacteria (the estrobolome) regulates circulating estrogen levels, while other microbes stimulate the production of intestinal serotonin, influencing inflammation and our mood.
The concept of the 'estrobolome'—the bacteria that regulate our estrogens—is scientifically validated by review journals (notably in MDPI) that detail how our microbes influence the assimilation of these hormones. Furthermore, fundamental research (such as work from UCLA) confirms that nearly 90% of our serotonin, the molecule of serenity, is produced in the gut through the stimulation of our bacteria. A recent observational and modeling study published in Cell Reports even shows that certain microbial strains can directly synthesize this molecule. The influence of the gut on overall inflammation and mood is also supported by a robust body of observational evidence and narrative reviews describing the gut-brain axis. However, while these biological links are real, clinical evidence such as randomized controlled trials (RCTs) in humans remains limited for recommending standardized wellness solutions. Presenting these interactions as a simple and immediate lever for acting on hormonal balance is therefore slightly premature, though the scientific path is extremely promising.
Aim for a daily fiber intake of 25 g (favoring seeds, legumes, or psyllium) to optimize gut microbiome balance, balance metabolic energy, and support mood via the gut-brain axis.
This recommendation to aim for 25 g of fiber per day is based on particularly solid scientific foundations. Regarding the microbiome, a systematic review published in the journal *Nutrients* confirms that fiber fermentation produces butyrate, a valuable compound that nourishes our digestive cells and maintains a calm intestinal environment. In terms of metabolic vitality, a large meta-analysis of clinical trials published in *The American Journal of Clinical Nutrition* shows that soluble fibers help regulate the sugar response and support insulin sensitivity. For the gut-brain axis, recent work in the *Journal of Agricultural and Food Chemistry* confirms that the quality of our diet influences stress management and mood through chemical messengers produced in our gut. It must be noted, however, that the evidence directly linking fiber to improved overall mental clarity in humans remains primarily derived from observational studies and still requires further investigation. Finally, the use of psyllium is a backup option validated by wellness experts to easily bridge a daily intake deficit.
Cardiovascular wellness assessment for women should not be limited to late-stage cholesterol screening in their forties, but must integrate their overall health history very early on: pregnancy complications, hormonal disorders (such as PCOS), immune dysregulation, and the transition to menopause.
This message is perfectly aligned with the evolution of longevity science and female cardiovascular wellness. A major expert review published by Appelman et al. (2025) in the European Heart Journal confirms that a woman's life course—including her maternity experiences, hormonal balance, and immunity—profoundly influences the flexibility and vitality of her blood vessels well before her forties. Furthermore, a narrative review conducted by Tiwari et al. (2026) in Diagnostics demonstrates that immune health and hormonal history are cornerstone elements for anticipating and personalizing the monitoring of vascular energy. The idea of breaking down silos in body assessment to link hormonal wellness and overall vitality is therefore scientifically indisputable. However, while these biological links are clear, the tools to fluidly integrate all these dimensions into daily comprehensive health check-ups are still in the development stage and need to be generalized.
To preserve brain health and memory, one should not rely on a single pill or habit, but rather on the synergy of four pillars (the "stack"): physical exercise, the MIND diet, attention to heart health, and mental and social stimulation.
The concept of a habit "stack" to support mental acuity rests on particularly solid scientific foundations. The US POINTER randomized clinical trial, published in JAMA (2025), demonstrates that a combined approach incorporating movement, healthy eating, heart monitoring, and an active social life protects memory and cognitive faculties in mature adults. These large-scale results confirm the historic FINGER randomized clinical trial, validating the idea that these routines function best when combined. Regarding the reduction in memory loss risk of up to 56% by accumulating these habits, the creator correctly specifies that this is based on data from observational studies (such as the Rush University cohorts on the MIND diet). However, these percentages should be tempered: randomized clinical trials on the MIND diet alone (such as a 2023 study) reveal more subtle gains in concentration than expected. These figures therefore represent encouraging long-term associations rather than promises of cause-and-effect, an essential nuance that the creator herself takes care to provide.
Do not purchase NAD+ supplements in the hope of alleviating menopause-related discomforts (hot flashes, energy dips, sleep disturbances), as solid and rigorous scientific evidence is currently lacking.
Mary Claire Haver is entirely correct to highlight the limitations of the 2026 pilot study published in *Frontiers in Aging* by Holmes and his team. This open-label clinical trial, conducted on only 40 women for 7 days, indeed presents a high risk of bias due to the absence of a placebo group. Regarding the second study published in the journal *Science* by Yoshino and his collaborators (2021), it is indeed a rigorous randomized controlled trial (RCT). However, this work focused on the metabolic sphere by demonstrating an improvement in insulin sensitivity in postmenopausal women, without ever evaluating the classic physical or cognitive discomforts of the hormonal transition. Currently, no robust double-blind trial confirms the impact of NAD+ precursors on sleep, temperature variations, or mental clarity. Although research on cellular vitality is fascinating, the effectiveness of these molecules for daily hormonal well-being currently rests only on theoretical assumptions and isolated clinical observations.
Frequent nocturnal awakenings in middle-aged women (between 2 a.m. and 5 a.m.) are not solely due to daily stress, but are explained by fluctuations in estrogen and progesterone that alter cortisol regulation and prevent the stress response system from calming down during the night.
During perimenopause, scientific review articles, such as the one published in Sleep Disturbance and Perimenopause (PMC, 2025), confirm that fluctuating female hormones directly disrupt the quality of our sleep. Progesterone acts as a calming support by stimulating the brain's relaxation receptors; its gradual decline reduces this natural brake, promoting nocturnal awakenings. In parallel, clinical observation studies, such as those shared by the Stanford Sleep Health Program, highlight that the drop in estrogen weakens our ability to modulate cortisol, the hormone of alertness. Without the regulatory shield of these hormones, our stress response system becomes more reactive, which can cause unexpected spikes of alertness in the middle of the night. Furthermore, the 2 a.m. to 5 a.m. window physiologically coincides with the time when our body temperature varies and cortisol begins its natural rise, two phenomena strongly disrupted by the hormonal transition. Research thus validates this complex interaction: these awakenings are not just a matter of mental load, but reflect a temporarily heightened biological sensitivity.
Decreases in sexual desire, discomfort during intercourse, and difficulty reaching orgasm during menopause are normal and common biological changes, and concrete solutions exist to regain comfort and pleasure.
Research broadly confirms that midlife hormonal fluctuations directly affect intimate well-being. The large-scale observational SWAN (Study of Women's Health Across the Nation) study shows a significant increase in decreased desire and discomfort during the transition to menopause. Regarding solutions, a meta-analysis of randomized controlled trials (RCTs) published in the journal Climacteric validates the efficacy of topical applications for restoring the comfort and suppleness of intimate tissues. In terms of desire itself, the 2019 Global Consensus (an evidence-based expert opinion) supports the efficacy of certain targeted hormonal adjustments. While presenting these variations as 'almost entirely manageable' is highly optimistic (as desire is also linked to relationship dynamics and stress), the creator's destigmatizing approach is based on extremely solid scientific foundations.
After menopause, the drop in hormones often weakens the balance of the intimate area. Using gentle local estrogen formulas can help restore optimal comfort and effectively prevent recurrent discomfort or urinary issues.
Dr. Haver highlights an essential yet taboo subject: the impact of menopause on the balance of the intimate and urinary areas. Research fully supports her protective approach, confirming that local care of this area is a key to well-being that should not be overlooked. A 2020 meta-analysis, encompassing several randomized clinical trials (RCTs), shows that the application of local estrogen reduces the risk of recurrent urinary discomfort by nearly 58% compared to a placebo. Furthermore, consensus guidelines published in 2025-2026 by the American Urological Association (AUA) and the American Urogynecologic Society (AUGS) place these gentle local formulas as a first-line treatment to restore intimate comfort. Unlike mood fluctuations or hot flashes, these intimate sphere discomforts tend to worsen over time if left unaddressed, which validates the importance of early intervention.
Slow walking does not replace a real workout session (cardio or strength training), but breaking up prolonged sitting (more than 6 to 8 hours per day) with light movement is essential for preserving longevity, regardless of one's regular workouts.
The creator's finding that prolonged sedentary behavior constitutes an independent risk, distinct from a lack of exercise, is scientifically very robust. She rightly relies on the meta-analysis by Patterson et al. (2018), based on large-scale observational studies, which shows that cumulative sitting time of more than 6 to 8 hours per day impairs heart health and longevity, even in active individuals. Furthermore, it is entirely accurate that slow walking is not enough to develop endurance or aerobic fitness, goals that require more sustained effort. However, data in movement science confirm that replacing short moments of sedentary time with light activity provides real benefits in terms of vitality. This clear distinction between the need to break up inactivity and the importance of training with intensity is therefore perfectly validated by current research.
Preventing fractures and protecting bone health should not wait until age 65 or the onset of osteoporosis; one must act during the menopause transition, a period when bone loss accelerates, by adopting a comprehensive and personalized approach.
The post draws on a viewpoint by researcher Susan M. Ott in the journal *JAMA* (July 2026), an expert opinion emphasizing that the prevention of bone fragility is too often overlooked in midlife women. Regarding the biology of well-being, the acceleration of bone density loss during the menopausal transition is a firmly established scientific fact. The large-scale SWAN observational study has demonstrated that women can lose a significant portion of their bone mass in the years surrounding the cessation of menstruation. To slow this decline, the utility of resistance (strength) training and an adapted nutritional profile is validated by systematic reviews as a pillar of strength and mobility. Conversely, the idea of routinely undergoing a baseline bone scan (DEXA) during perimenopause remains debated: consensus guidelines (such as the USPSTF) generally recommend it at age 65, except in the presence of specific risk factors (genetics, constitutional thinness) where early screening is fully justified.
Endometriosis does not automatically disappear with menopause, pregnancy, or the removal of the uterus, and these events should not be considered miracle cures.
This assessment is fully consistent with current knowledge regarding female physiological balance. A synthesis by the World Health Organization (WHO, expert opinion) confirms that there is no way to permanently eliminate these tissues that develop outside their usual area. Regarding the removal of the uterus, a review of observational studies published in *Facts, Views, and Vision in ObGyn* reveals that nearly 21% of women continue to experience physical discomfort after this procedure. Another analysis of observational literature in *Human Reproduction Update* explains that if the fertility glands are preserved, their activity continues to stimulate these sensitive tissues. When cycles cease naturally, clinical (observational) follow-ups show that remaining tissues can stay active due to hormones still produced by other parts of the body, notably body fat. Likewise, while pregnancy offers a welcome pause, observational data confirm that it does not definitively clear the body of these tissues. This message is therefore very valuable for dispelling false promises and guiding toward realistic support for female comfort.
The decline in estradiol during perimenopause and menopause is the direct biological cause of disturbances in sleep, mood, metabolism, and physical fitness.
Scientific research largely validates the message of this publication. Regarding sleep and mood, the recommendations of The Menopause Society (based on randomized controlled trials) confirm that hormonal fluctuations disrupt body temperature regulation and the brain chemistry linked to well-being. Concerning metabolism, the large observational SWAN study shows that the hormonal transition naturally promotes a redistribution of fat toward the abdominal area and slows the basal metabolic rate. Finally, meta-analyses published in the Journal of Clinical Endocrinology and Metabolism attest to the key role of estrogens in preserving bone mass and muscular vitality. Although other factors such as daily stress or natural aging coexist, attributing these variations in fitness to the decline in estradiol is based on extremely solid biological foundations.
To preserve and rebuild your gut microbiota after taking antibiotics (which can disrupt it for several years), you should focus on the pillars of nutrition: fiber, protein, and fermented foods.
Research confirms that antibiotic use can alter the diversity of our gut flora over the long term. An observational study published in Nature Microbiology by Palleja et al. (2018) shows that while the flora largely reconstitutes itself after six months, certain species of beneficial bacteria may take more than a year to reappear. Regarding reconstruction, the importance of fiber and fermented foods is strongly supported by science. Notably, a randomized controlled trial (RCT) conducted by Wastyk et al. (2021) in the journal Cell proved that a diet rich in fermented foods increases microbiota diversity and reduces markers of inflammation. Conversely, the role of protein is more nuanced: while essential to the body, excess protein without sufficient fiber intake can sometimes promote bacteria that are less friendly to our gut. The overall impact of this microbiota on immunity and general balance is now widely validated, making this approach highly relevant for daily well-being.
Discomforts related to the cycle and the pelvic region (cramping, heavy flow, intimate discomfort) are very common but should not be considered normal; it is essential to seek answers to preserve one's well-being.
The awareness message that rejects the normalization of intimate discomfort and difficult cycles is supported by solid research data. The statistic indicating that up to 80% of women develop fibroids (small benign growths) during their lifetime comes from benchmark observational cohort studies (notably from the US NIH), even if many of them do not experience any daily discomfort. For endometriosis, the assessment of a 7-year diagnostic delay is unfortunately validated by reports from international organizations like the WHO, which highlight the impact of minimizing these severe tensions on quality of life. The overall figure of 90% of women affected by a challenge related to their intimate balance during their lifetime is explained by the high frequency of painful periods, which affect an immense majority of the female population according to public health surveys. Committees of women's health experts agree that listening to one's body and compassionate support are essential to overcoming these imbalances in daily life.
Perimenopause begins well before age 50 and impacts overall health (brain, heart, bones); it is advisable to get informed early to approach this transition in a proactive, calm, and fearless manner.
Scientific research confirms that perimenopause often begins as early as the early forties, well before the permanent cessation of menstruation. The large observational SWAN (Study of Women's Health Across the Nation) study demonstrates that this hormonal transition is effectively linked to changes in bone health, lipid profiles, and cognitive function, and is not limited to hot flashes. Furthermore, recommendations from the Menopause Society (expert opinion) highlight that early education helps reduce anxiety and optimize general well-being. The reassuring idea of demystifying this stage is scientifically relevant, even if the data remind us that the intensity of manifestations varies considerably from one person to another. Thus, the call for a comprehensive and preventive approach to women's vitality is solidly validated by science.
Decreased libido, pain during intercourse, and urinary discomfort linked to menopause are not an inevitability of aging, but rather physiological manifestations that are manageable through an understanding of hormones (estrogen, testosterone), perineal care, and at-home wellness rituals.
Science broadly validates the fact that intimate discomforts of menopause are linked to hormonal fluctuations and remain manageable. A review by the North American Menopause Society (type: expert consensus and clinical trials) confirms that the drop in estrogen directly alters the hydration and comfort of intimate tissues, but that gentle, local solutions are very effective. Furthermore, a global consensus position published in The Lancet Diabetes & Endocrinology (type: meta-analysis of randomized clinical trials) supports that testosterone adjustment can significantly revive desire and pleasure during this period of life. The emphasis on perineal education is also pertinent, as muscle tension in this area is often a source of blockages and pain. While presenting these disorders as 'completely treatable' is slightly optimistic for multifactorial situations (which include relational or stress factors), the creator's proactive and educational approach is based on solid scientific foundations.
What's more nuanced than that
The use of vaginal estrogen in women prone to recurrent urinary discomfort significantly reduces the risk of hospitalization, severe infectious complications, and mortality (by 60 to 80%), even though this supportive treatment is currently prescribed to only 5% of these women.
The study by LaClair et al. (2026), published in the journal Urology, is a vast observational analysis based on real-world data from nearly 1.9 million women. This type of evidence (retrospective database study) is ideal for observing large-scale trends, but it cannot establish a direct cause-and-effect relationship. The data indeed show that women who received a prescription for local hormonal care exhibited significantly lower rates of hospitalization, severe infections, and death. Nevertheless, directly attributing a 60 to 80% reduction in mortality to this routine alone is an oversimplification, as the study did not adjust its results for other lifestyle habits or the overall health status of the participants. It is highly probable that a "healthy user effect" is at play, as individuals who access this type of care often have more rigorous lifestyle and wellness regimens. Finally, the finding that only 5% of the women in question initially receive this treatment option is accurate and underscores a significant lack of access to these women's health solutions.
Emotional well-being follows a U-shaped curve over the course of life, reaching its lowest point around ages 47-48 (a phase that often coincides with perimenopause and various midlife stressors) before rising again, making this difficult transition an opportunity for personal reconnection.
The existence of a U-shaped happiness curve with a midlife nadir is a widely studied concept. A large observational study conducted by economist David Blanchflower (2020) across 132 countries indeed confirms that subjective well-being tends to hit a nadir around ages 47-48 before trending upward. However, this model is a subject of debate: longitudinal analyses (such as that by Galambos et al. in 2020) instead suggest that happiness remains stable or increases slightly during adulthood, challenging the universal nature of this dip. The association of this period with the challenges of perimenopause is well-documented; data from the observational SWAN (Study of Women's Health Across the Nation) study show increased vulnerability to stress and sleep disturbances during this transition. Thus, while the U-shaped curve is not an absolute truth for everyone, the idea of a rebound in well-being following a demanding life transition is scientifically coherent.
The use of vaginal estrogen by women prone to frequent urinary imbalances is presented as the best underutilized tool for preventing serious physical complications and extending life.
The large-scale observational cohort study published in the journal Urology (2026) by Justin LaClair's team indeed shows an impressive correlation between the use of local estrogen and a decrease in overall physical complications in women with recurrent intimate imbalances. This gentle, local approach is solidly supported by meta-analyses of randomized controlled trials and recommended by experts at the American Urological Association (AUA, updated in 2025) to regulate flora and preserve urinary comfort. As the creator herself lucidly admits, these data remain observational and do not demonstrate direct causality. There is a strong 'healthy-user bias,' as individuals accessing this type of intimate optimization often benefit, in parallel, from much more rigorous lifestyle and general health monitoring. Presenting local estrogen as a direct solution for preventing death is therefore an exaggerated statement in relation to the state of clinical research. This method nonetheless remains a strategy for longevity and comfort of remarkable value, validated for daily well-being but still offered too infrequently.
The redistribution of fat toward the abdominal region during menopause (the "menopause belly") is a real and predictable biological change linked to declining estrogen, rather than a lack of willpower, which makes the classic caloric restriction strategy ("eat less, move more") unsuitable.
Research solidly validates the existence of the "menopause belly": the longitudinal observational SWAN study shows that declining estrogen leads to a measurable redistribution of fat from the hips to the abdomen in the form of visceral fat. Scientific literature reviews confirm that this morphological change is biological in nature. However, regarding overall weight gain, a benchmark study on energy expenditure (Pontzer et al., Science) shows that the metabolic slowdown during this period of life is primarily linked to general aging and the natural loss of muscle mass, rather than menopause itself. The advice not to rely solely on "eating less" is quite relevant: overly severe caloric restrictions risk breaking down muscle mass, which further weakens resting energy expenditure. Finally, the British Menopause Society guidelines agree that it is preferable to focus on dietary quality and muscle strengthening to support metabolic health.
There is reportedly a target estradiol level of approximately 60 pg/mL in the blood to protect the heart and bones of postmenopausal women. The most common hormone therapy patches are said to achieve this level, suggesting the benefit of measuring this rate via blood test to optimize long-term well-being.
The creator relies on a very recent study by Piette and Simon published in Gynecological Endocrinology (July 2026), which models data to propose this target of 60 pg/mL to optimize bone and cardiovascular well-being. This analysis is based on a comparison with large randomized clinical trials (the KEEPS and ELITE trials), showing that the observed benefits often coincide with this blood concentration level. However, this is a theoretical extrapolation and not new direct evidence that routine blood monitoring improves longevity. Current scientific consensus does not recommend measuring estradiol to adjust hormone therapy, as these levels fluctuate naturally and evaluation is primarily based on symptoms. Furthermore, the use of these hormones for purely preventive purposes for the heart has not yet been validated by health authorities. The creator herself judiciously nuances her statement by speaking of a 'signal' rather than an official recommendation, which is scientifically rigorous.
To counter the loss of muscle tone during the menopause transition, three essential levers must be activated: muscle strengthening (the stimulus), adequate protein intake (the building blocks), and the balance of hormones such as estrogen and testosterone.
The importance of muscle strengthening and protein for maintaining physical fitness during menopause is firmly established by research. A major meta-analysis (Tan et al., 2023, published in BMC Women's Health) encompassing 27 randomized clinical trials confirms that resistance training is the only type of exercise that significantly increases lean mass in menopausal women. Furthermore, recent clinical trials show that the muscles of menopausal women respond extremely well to this physical stimulus. As for protein, its structural role is undeniable, even if clinical data on increased nutritional needs specific to this transition period remain of moderate quality (2024 narrative review, MDPI). Conversely, the direct influence of declining estrogen on muscle loss is often exaggerated. A comprehensive review (Menzies et al., 2026, published in the Journal of Cachexia, Sarcopenia and Muscle) indicates that the decline in muscle vitality observed during this period is primarily linked to general aging and reduced physical activity, rather than to hormonal decline alone. This same study shows that estrogen supplementation alone has a negligible impact on muscle gain, confirming that movement remains the most powerful signal for stimulating growth.
The decline in estrogen after age 40 accelerates the loss of skin collagen, making collagen supplementation particularly relevant and effective for mature women compared to younger ones.
It is physiologically established that the drop in estrogen during the transition of one's forties accelerates the reduction of cutaneous collagen, a fact widely documented by observational research. Regarding supplementation, a broad review of meta-analyses published in the Aesthetic Surgery Journal (2026) supports that hydrolyzed collagen promotes skin hydration and elasticity. Nevertheless, a meta-analysis of randomized controlled trials (RCTs) published by Dr. Myung in the American Journal of Medicine (2025) provides a significant caveat, showing that meaningful benefits primarily stem from low-quality or industry-funded studies. The assertion that collagen supplementation specifically targets and corrects the loss of firmness due to hormonal decline after age 40 therefore remains an appealing but exaggerated extrapolation. Although these supplements provide useful molecular building blocks for protein synthesis, solid and independent evidence that they can directly counteract the cutaneous effects of menopause is still lacking.
Progesterone is an essential and often underestimated ally for optimizing sleep and soothing cycle-related discomforts (PMS, PMDD), while transdermal estradiol remains the indispensable hormone that should not be overlooked for maintaining balance.
The positive impact of progesterone on restless nights rests on a solid scientific foundation: a meta-analysis of randomized controlled trials (RCTs) conducted by Nolan's team confirmed that it improves subjective sleep quality and accelerates sleep onset by activating the brain's calming receptors. Furthermore, a randomized controlled trial from the University of British Columbia highlights its effectiveness in calming nocturnal thermal fluctuations during life transitions. Conversely, the notion that it directly relieves PMS and PMDD is highly debated. A systematic review by the Cochrane Collaboration indicates that progesterone shows no benefit superior to a placebo for these mood fluctuations. Research suggests instead that PMDD discomfort stems from increased neuronal sensitivity to this hormone, which aligns with the fact that some individuals do not tolerate it well. Finally, regarding transdermal estradiol, a literature review published in Frontiers supports that its application helps stabilize physical and emotional well-being when carefully combined with progesterone.
Hormone therapy for menopause must be personalized and adapted to each woman, as the dose required to relieve immediate symptoms (such as hot flashes or sleep disturbances) is not necessarily the same as that required to protect long-term health (such as bone strength), as hormone absorption varies from one person to another.
The observation that menopause affects overall well-being (sleep, bone strength, hair quality) is solidly validated by research. For example, the guidelines from the North American Menopause Society (NAMS, expert consensus) confirm that hormone therapy helps maintain bone strength and relieve intimate discomfort. The assertion that dosages must be personalized is also supported: the British Menopause Society (BMS, clinical practice recommendations) advocates for a tailored approach, adjusted according to individual tolerance. Regarding the idea that a dose that eases symptoms does not necessarily provide long-term protection, reviews of randomized clinical trials (RCT) show that even very low doses of hormones are generally sufficient to preserve bone density. Saying that feeling well does not mean being protected is therefore slightly exaggerated, as the protective effect on the skeleton is activated at even the lowest clinical dosages. Nevertheless, the individual variability of hormone absorption depending on the format used (transdermal or oral) is a well-documented biological fact that fully justifies personalized follow-up.